Postoperative quality of life after gastrectomy in gastric cancer patients: a prospective longitudinal observation study

Chao-Jie Wang1,2,*, Yun-Suhk Suh1,3,*, Hyuk-Joon Lee1,4, Ji-Hyeon Park1,4, Shin-Hoo Park1,4, Jong-Ho Choi1,7, Fadhel Alzahrani1,8, Khalid Alzahrani1,9, Seong-Ho Kong1,4, Do-Joong Park1,4, Hui Cao2, Han-Kwang Yang1,4

1Department of Surgery, Seoul National University Hospital, Seoul, Korea
2Department of Gastrointestinal Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
3Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea
4Cancer Research Institute, Seoul National University, Seoul, Korea
5Department of Surgery, Gachon University Gil Medical Center, Incheon, Korea
6Division of Foregut Surgery, Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
7Department of Surgery, Eulji University, Seoul, Korea
8Department of Surgery, Al-Noor Specialist Hospital, Makkah, Saudi Arabia
9Department of Surgery, Taif University, College of Medicine, Taif, Saudi Arabia

Received January 26, 2022, Revised May 18, 2022, Accepted June 2, 2022

Corresponding Author: Hyuk-Joon Lee
Department of Surgery, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-1957, 2318, Fax: +82-2-766-3975
E-mail: app98@snu.ac.kr
ORCID: https://orcid.org/0000-0002-9530-647X

Purpose: The European Organization for Research and Treatment of Cancer quality of life (QOL) questionnaires (QLQ-C30, QLQ-OG25, and QLQ-STO22) are widely used for the assessment of gastric cancer patients. This study aimed to use these questionnaires to evaluate QOL in postgastrectomy patients.

Methods: We prospectively evaluated 106 patients with distal gastrectomy (DG), 57 with pylorus-preserving gastrectomy (PPG), and 117 with total gastrectomy (TG). Body weight and QOL questionnaires were evaluated preoperatively and postoperatively (at 3 weeks, and 3, 6, and 12 months).

Results: TG patients had significantly more weight loss than DG/PPG patients. Compared with DG, patients after PPG had less dyspnea (P = 0.008) and trouble with coughing (P = 0.049), but more severe symptoms of insomnia (P = 0.037) and reflux (P = 0.030) at postoperative 12 months. Compared with DG/PPG, TG was associated with worse body image, dysphagia, eating, and taste in both OG25 and STO22. Moreover, OG25 revealed worse QOL in the TG group with respect to odynophagia, eating with others, choked when swallowing, trouble talking, and weight loss. The QOL of patients who received chemotherapy was worse than those in the chemo-free group in both physical functioning and symptoms such as nausea/vomiting, appetite loss, and trouble with taste; however, these side effects would soon disappear after finishing chemotherapy.

Conclusion: PPG was similar to DG in terms of postoperative QOL and maintaining body weight, while TG was always inferior to both DG and PPG. Adjuvant chemotherapy can affect both body weight and QOL despite being reversible.

Key Words: Chemotherapy, European Organization for Research and Treatment of Cancer quality of life, Gastrectomy, Quality of life, Weight loss
INTRODUCTION

Gastric cancer is a health problem, which remains the 5th most common cancer worldwide. In recent years, with the development of screening program and comprehensive treatment, gastric cancer prognosis has been significantly improved [1]. More patients can have long-term survival after radical gastrectomy. Therefore, the postoperative quality of life (QOL) has become a big issue in addition to surgical oncological safety.

Nowadays, significant progress has been made in defining and measuring the QOL in patients after gastrectomy. Among the multiple measures, the QOL questionnaire QLQ-C30, which was designed by the European Organization for Research and Treatment of Cancer (EORTC), has been most extensively used [2]. C30 utilizes a 30-item questionnaire to evaluate the general condition of cancer patients [3,4]. Since C30 is not specialized for gastric cancer, STO22 has been developed for use among gastric cancer patients with varying disease stages and treatment modalities [5]. Moreover, the esophagogastric cancer module named OG25, with 7 different evaluation scales obtained from STO22, is also recommended to supplement C30 when assessing QOL in patients with esophageal, junctional or gastric cancer [6]. All the 3 questionnaires have been translated into Korean and were validated [7,8].

The extent of gastrectomy and reconstruction method both have been proposed to be related to postprandial symptoms and nutritional performance that can affect the QOL after gastrectomy [9,10]. A general consensus states that total gastrectomy (TG) has a certain detrimental impact on the postoperative QOL. when compared with partial gastrectomy including distal gastrectomy (DG) and pylorus-preserving gastrectomy (PPG) [8,9,11,12]. Despite the influences of different anastomosis types, such as gastroduodenal anastomosis in Billroth-I (DGBI), gastrointestinal anastomosis in Billroth-II (DGBII), and Roux-en-Y (DGRY), gastrogastrostomy in PPG still remains controversial [13-16]. In addition, the general condition of patients after gastrectomy usually changes from time to time [16]. A continuous follow-up of their QOL can help develop appropriate interventions to improve the QOL of gastric cancer patients.

In this study, we aimed to use C30, OG25, and STO22 to evaluate the QOL of postgastrectomy patients at different time points after surgery.

METHODS

The study was approved by the Institutional Review Board of the Seoul National University Hospital (No. 1406-108-590). Written informed consent for participation in the study was obtained from all participants.

Study participants

In this prospective study, patients with pathologically proven gastric adenocarcinoma who were expected to receive curative gastrectomy at the Seoul National University Hospital from July 2014 to May 2018 were enrolled. We excluded (1) patients who did not receive gastrectomy as their treatment modality, such as endoscopic submucosal dissection (ESD); (2) patients who did not receive curative (R0) resection; (3) patients who received combined resection; and (4) patients who recurred within 1 year after surgery.

Surgical and oncological outcomes

The following clinicopathologic data were collected and compared: age, sex, initial body weight, initial body mass index (BMI), surgical approach (open vs. minimally invasive), surgical procedures (DG vs. PPG vs. TG), pathological TNM stage, complications, and postoperative hospital stay. The severity of complications was classified according to the Clavien-Dindo classification system. Recurrence-free survival was determined by the image-based results from patients’ follow-up program [17].

Quality of life assessment

All patients were asked to fill out each questionnaire (C30, OG25, and STO22) 5 times: preoperatively, and at 3 weeks and 3, 6, and 12 months postoperatively. Furthermore, body weight was checked at every visit using the same electronic scale for all patients. All questionnaires and anthropometric data were recorded using a table-PC and were automatically transferred to an electronic medical record. The body weight loss percentage was calculated by the formula: (initial body weight – current body weight) / initial body weight × 100%.

Statistics

Statistical analyses were performed using the IBM SPSS Statistics ver. 22.0 (IBM Corp., Armonk, NY, USA) and Prism 8 (GraphPad, San Diego, CA, USA) software. Clinicopathologic features and complications were compared using the chi-square test. Quantitative surgical data including body weight, BMI, and hospital stay was compared using the Student t-test. The weight loss percentage was compared using the 1-way analysis of variance. The mean scores of each scale in the QOL questionnaires were compared between each surgery group by the Student t-test. A P-value less than 0.05 was considered statistically significant.

RESULTS

Patient characteristics and surgical outcomes

In this study, 312 patients were selected, but 11 refused to participate. After applying the exclusion criteria, 21 cases with 4 who underwent ESD, 4 who received palliative
gastrojejunostomy. 1 who received concomitant distal pancreatectomy, and 12 who developed tumor recurrence during follow-up were excluded from this study (Supplementary Table 1). Among the 280 eligible patients, 106, 57, and 117 underwent DG (37.9%), PPG (20.6%), and TG (41.9%), respectively (Fig. 1).

Clinicopathologic features and surgical data of these 280 cases are shown in Table 1. In the DG group, 77 patients received Billroth-I reconstruction (72.6%), 19 received Billroth-II (17.9%), and 10 with Roux-en-Y anastomosis (9.4%). More male patients were observed in TG than in PPG (69.2% vs. 50.9%, P = 0.029). The proportion of minimally invasive surgery was increasing from 78.6% in TG, 89.6% in DG to 100% in PPG (P < 0.001). Further, the proportion of stage I cases was 73.5%, 85.8%, and 98.2% in TG, DG, and PPG, respectively (P < 0.001). Although no significant difference was observed in the postoperative complications among the 3 groups, more delayed gastric emptying (DGE) was observed in PPG than in DG (8.8% vs. 0.9%, P = 0.020). However, there was no significant difference in age, initial body weight, initial BMI, and hospital stay.

For further QOL analysis, we set up a chemo-free subgroup with patients free from adjuvant chemotherapy to reduce bias, and 91, 56, and 88 cases in DG, PPG, and TG were redistributed, respectively. Clinicopathologic features and surgical data of these 235 cases in the chemo-free subgroup are shown in Supplementary Table 2. The proportion of minimally invasive surgery was 93.2% in TG, 96.7% in DG, and 100% in PPG. The proportion of stage I cases was 97.7%, 100%, and 100% in TG, DG, and PPG, respectively. Not only the surgical approach, but also the TNM stage. showed no statistical difference among DG, PPG, and TG in this subgroup analysis.

**Follow-up data**

The questionnaire completion rates are shown in Fig. 1. All participants were free from tumor recurrence during follow-up (Supplementary Fig. 1). Forty-five patients (16.1%) received adjuvant chemotherapy according to the treatment guideline. All of them started chemotherapy after postoperative 3 weeks. Twenty-five patients finished the course before postoperative 6 months, while the rest finished it before 1 year. The chemotherapy rate was 14.2%, 1.8%, and 24.8% in DG, PPG, and TG, respectively (Table 1).

**Body weight loss according to operation type and adjuvant chemotherapy**

The body weight loss percentage was compared at each time point. In the chemo-free subgroup analysis, there is no significant difference between DGBI (n = 67) and DGBII/DGRY (n = 24), as shown in Fig 2A. When compared among DG (n = 91), PPG (n = 56), and TG (n = 88), patients who underwent
### Table 1. Demographic features and clinical information of patients

| Characteristic                          | DG group | PPG group | TG group | Total | P-value |
|-----------------------------------------|----------|-----------|----------|-------|---------|
|                                        |          |           |          |       | DG vs. PPG | DG vs. TG | PPG vs. TG |
| No. of patients                         | 106      | 57        | 117      | 280   | 0.333   | 0.532 | 0.117 |
| Age (yr)                                | 56.1 ± 8.9 (34–76) | 54.7 ± 9.8 (33–72) | 57.0 ± 8.9 (31–75) | 56.2 ± 9.2 (31–76) | 0.333 | 0.532 | 0.117 |
| Sex                                     |          |           |          |       | 0.509   | 0.070 | 0.029* |
| Male                                    | 60 (56.6) | 29 (50.9) | 81 (69.2) | 170 (60.7) | 0.509 | 0.070 | 0.029* |
| Female                                  | 46 (43.4) | 28 (49.1) | 36 (30.8) | 110 (39.3) | 0.509 | 0.070 | 0.029* |
| Initial body weight (kg)                | 63.9 ± 10.9 (37.9–87.6) | 64.8 ± 9.7 (45.7–93.0) | 65.2 ± 9.9 (43.0–90.0) | 64.6 ± 10.3 (37.9–93.0) | 0.621 | 0.354 | 0.782 |
| Initial BMI (kg/m²)                     | 24.0 ± 3.1 (16.8–35.0) | 23.9 ± 2.8 (16.0–31.7) | 23.9 ± 2.6 (18.6–30.5) | 23.9 ± 2.8 (16.0–35.0) | 0.914 | 0.887 | 0.997 |
| Surgical approach                       |          |           |          |       | 0.009* | 0.029* | <0.001* |
| Open                                    | 11 (10.4) | 0 (0)     | 25 (21.4) | 36 (12.9) | 0.009* | 0.029* | <0.001* |
| Laparoscopy/robotic                     | 95 (89.6) | 57 (100)  | 92 (78.6) | 244 (87.1) | 0.009* | 0.029* | <0.001* |
| Reconstruction method                   |          |           |          |       |          |          |          |
| Billroth I                              | 77 (72.6) | NA        | NA       | NA    | NA      | NA       | NA |
| Billroth II                             | 19 (17.9) | NA        | NA       | NA    | NA      | NA       | NA |
| Roux-en-Y                               | 10 (9.4)  | NA        | NA       | NA    | NA      | NA       | NA |
| Gastrogastrectomy                       | NA       | 57 (100)  | NA       | NA    | NA      | NA       | NA |
| Esophagojejunostomy                     | NA       | NA        | 117 (100) | NA   | NA      | NA       | NA |
| Pathological stage<sup>a</sup>          |          |           |          |       |         |          |          |
| I                                       | 91 (85.8) | 56 (98.2) | 86 (73.5) | 233 (83.2) | 0.032* | 0.041* | <0.001* |
| II                                      | 10 (9.4)  | 0 (0)     | 15 (12.8) | 25 (8.9)  | 0.032* | 0.041* | <0.001* |
| III                                     | 5 (4.7)   | 1 (1.8)   | 16 (13.7) | 22 (7.9)  | 0.032* | 0.041* | <0.001* |
| Complication                            |          |           |          |       |          |          |          |
| None                                    | 86 (81.1) | 49 (86.0) | 92 (78.6) | 227 (81.1) | 0.227 | 0.880 | 0.135 |
| CD grade I–II                           | 9 (8.5)   | 1 (1.8)   | 12 (10.3) | 22 (7.9)  | 0.227 | 0.880 | 0.135 |
| CD grade III–IV                         | 11 (10.4) | 7 (12.3)  | 13 (11.1) | 31 (11.1) | 0.227 | 0.880 | 0.135 |
| Delayed gastric emptying                |          |           |          |       |          |          |          |
| No                                      | 105 (99.1) | 52 (91.2) | NA       | NA     | 0.020* | NA       | NA |
| Yes                                     | 1 (0.9)   | 5 (8.8)   | NA       | NA     | 0.020* | NA       | NA |
| Hospital stay (day)                     | 11.2 ± 8.8 (6–54) | 9.9 ± 6.8 (7–39) | 10.4 ± 6.2 (6–38) | 10.6 ± 7.4 (6–54) | 0.325 | 0.440 | 0.609 |
| Adjuvant chemotherapy                   |          |           |          |       |          |          |          |
| No                                      | 91 (85.8) | 56 (98.2) | 88 (75.2) | 235 (83.9) | 0.011* | 0.063 | <0.001* |
| Yes                                     | 15 (14.2) | 1 (1.8)   | 29 (24.8) | 45 (16.1) | 0.011* | 0.063 | <0.001* |

Values are presented as number only, mean ± standard deviation (range), or number (%).

DG, distal gastrectomy; PPG, pylorus-preserving gastrectomy; TG, total gastrectomy; BMI, body mass index; NA, not applicable; CD, Clavien-Dindo classification.

<sup>a</sup>Classification according to the American Joint Committee on Cancer 8th edition.

*P < 0.05, statistically significant.
TG showed significantly more body weight loss compared to those who underwent DG and PPG. The difference started at postoperative 3 weeks (P = 0.020), and steadily increased until postoperative 12 months (P < 0.001). However, no significant difference was detected between DG and PPG during follow-up (Fig. 2B).

In the combined chemotherapy cases, patients who underwent partial gastrectomy alone (n = 147) exhibited significantly less body weight loss compared to those who underwent partial gastrectomy with adjuvant chemotherapy (n = 16) at 3 months after surgery (P = 0.037), but no significant difference at 3 weeks, 6, and 12 months after surgery (Fig. 2C). In patients who underwent TG, cases with chemotherapy (n = 29) also had more body weight loss compared with those who received surgery alone (n = 88) at postoperative 3 months (P < 0.001) and 6 months (P = 0.004), while no difference at 3 weeks and 12 months (Fig. 2D).

**Comparison of C30 scores among postgastrectomy patients without chemotherapy**

There was no significant difference in each individual score of C30 among the DG, PPG, and TG groups before surgery, except for the emotional functioning, which was better in DG than PPG (P = 0.018).

In Table 2 and Fig. 3, between DG and PPG, only the dyspnea symptom scale was observed better in PPG at postoperative 3 months (P = 0.023) and maintained until 1 year (P = 0.008). In addition, between DG and TG, DG was associated with significantly better scores for 9 out of 15 scales in C30 at postoperative 3 weeks. Global health status, physical functioning, role functioning, fatigue, nausea/vomiting, and appetite loss were observed better in DG at 2 time points or more during follow-up. However, all these significant differences disappeared at postoperative 12 months. In the comparison between PPG and TG, 5 out of 15 scales were observed with significantly better scores in the PPG group at postoperative 3 months. Global health status, diarrhea, dyspnea, and appetite loss were observed with significantly better scores...
Table 2. Comparison of mean scores on EORTC QLQ-C30 among DG ($n = 91$), PPG ($n = 56$), and TG ($n = 88$), without chemotherapy

| Scale name                        | DG vs. TG | PPG vs. TG | DG vs. PPG |
|-----------------------------------|-----------|------------|------------|
|                                   | Time after surgery | Time after surgery | Time after surgery |
|                                   | 3 Wk  | 3 Mo | 6 Mo | 12 Mo | 3 Wk  | 3 Mo | 6 Mo | 12 Mo | 3 Wk  | 3 Mo | 6 Mo | 12 Mo |
| Global health status/QOL          | 56:46*** | 58:55 | 61:55* | 61:60 | 54:46* | 59:55 | 60:55* | 67:60 | 56:54 | 58:59 | 61:60 | 61:67 |
| Functional scale                  |          |          |       |       |       |       |       |       |       |       |       |       |
| Physical functioning              | 82:78*** | 86:83* | 87:83* | 86:85 | 79:78 | 85:83 | 88:83* | 87:85 | 82:79 | 86:85 | 87:88 | 86:87 |
| Role functioning                  | 79:73*** | 81:79 | 86:79*** | 87:83 | 71:73 | 82:79 | 83:79 | 88:83 | 79:71*** | 81:82 | 86:83 | 87:88 |
| Emotional functioning             | 85:78*** | 81:80 | 83:82 | 84:82 | 82:78 | 83:80 | 82:82 | 84:82 | 85:82 | 81:83 | 83:82 | 84:84 |
| Cognitive functioning             | 89:88    | 85:87 | 83:87 | 83:86 | 90:88 | 88:87 | 84:87 | 87:86 | 89:90 | 85:88 | 83:84 | 83:87 |
| Social functioning                | 84:79*** | 84:78 | 87:83 | 88:84 | 80:79 | 85:78* | 84:83 | 88:84 | 84:80 | 84:85 | 87:84 | 88:88 |
| Symptom scale                     |          |          |       |       |       |       |       |       |       |       |       |       |
| Fatigue                           | 32:39*   | 30:34 | 27:34*** | 27:32 | 38:39 | 31:34 | 31:34 | 27:32 | 32:38* | 30:31 | 27:31 | 27:27 |
| Nausea and vomiting               | 11:13    | 11:20*** | 9:15*** | 8:12 | 11:13 | 9:20*** | 12:15 | 11:12 | 11:11 | 11:9 | 9:12 | 8:11 |
| Pain                              | 19:26*** | 14:13 | 10:11 | 11:11 | 22:26 | 13:13 | 10:11 | 8:11 | 19:22 | 14:13 | 10:10 | 11:8 |
| Dyspnea                           | 11:16    | 11:12 | 10:11 | 10:13 | 11:16 | 5:12*** | 5:11* | 4:13*** | 11:11 | 11:5* | 10:5 | 10:4*** |
| Insomnia                          | 17:26*** | 13:17 | 13:16 | 9:15 | 24:26 | 18:17 | 18:16 | 18:15 | 17:24 | 13:18 | 13:18 | 9:18*** |
| Appetite loss                     | 26:34*** | 15:33* | 11:24*** | 14:20 | 31:34 | 19:33*** | 22:24 | 12:20* | 26:31 | 15:19 | 11:22** | 14:12 |
| Constipation                      | 19:16    | 15:16 | 11:12 | 15:11 | 18:16 | 19:16 | 17:12 | 18:11 | 19:18 | 15:19 | 11:17 | 15:18 |
| Diarrhea                          | 17:21    | 23:30 | 23:29 | 31:30 | 17:21 | 20:30* | 19:29* | 23:30 | 17:17 | 23:20 | 23:19 | 31:23 |
| Financial difficulties            | 12:19    | 13:17 | 14:15 | 11:13 | 12:19 | 12:17 | 11:15 | 11:13 | 12:14 | 13:12 | 14:11 | 11:11 |

Values are presented as mean scores.

EORTC QLQ, European Organization for Research and Treatment of Cancer QOL questionnaires; DG, distal gastrectomy; TG, total gastrectomy; PPG, pylorus-preserving gastrectomy; QOL, quality of life.

*Higher scores represent better QOL; †lower scores represent better QOL; ¥DG obtains better QOL in the comparison; ¥¥PPG obtains better QOL in the comparison.

*P < 0.05, **P < 0.01.
Patients after PPG revealed no significantly better QOL than those after DG, while both were superior to TG at 1 year postoperatively according to the C30 questionnaire.

Comparison of OG25 and STO22 scores among postgastrectomy patients without chemotherapy

For the baseline analysis, only the symptom of pain in OG25 was significantly better in TG compared with DG (P = 0.035). In contrast, no other difference was observed among the 3 groups before surgery.

In Table 3 and Fig. 4, the symptom of trouble with coughing in OG25 (P = 0.049) showed significantly worse in DG than in PPG at postoperative 12 months, while the symptom of reflux in STO22 (P = 0.030) showed significantly better in DG than in PPG. When compared between DG and TG, the 7 scales in OG25 appeared significantly better in DG at 3 time points or more, and 6 of them (body image, dysphagia, eating, odynophagia, eating with others, and weight loss) in OG25 that appeared significantly better in PPG at 2 time points or more, whereas there were 3 scales (dysphagia, eating restrictions, and anxiety) in STO22. In addition, the symptom of reflux in STO22 showed significantly worse in PPG than in TG (P = 0.009).

Patients who underwent PPG and DG tended to have better QOL than TG at postoperative 1 year according to both OG25 and STO22. Moreover, these differences were more obvious in OG25 when compared with STO22.

Quality of life influenced by chemotherapy

There was no significant difference between the DG and DG plus chemotherapy group (DG + Chemo) or TG and TG plus chemotherapy group (TG + Chemo), preoperatively. At postoperative 3 weeks before chemotherapy was applied, emotional functioning (P = 0.039) and dyspnea (P = 0.004) in C30 showed significantly worse in the DG + Chemo group than in DG, and symptoms of appetite loss (P = 0.010), dry mouth (P = 0.029), and weight loss (P = 0.017) were more common in the TG + Chemo group than in TG.

Comparing the DG and DG + Chemo groups, physical functioning, nausea/vomiting, appetite loss, diarrhea in C30 and odynophagia, and trouble with taste, odynophagia in OG25 showed significantly worse in the DG + Chemo group.

Fig. 3. (A) Radar chart representing mean scores of the EORTC QLQ-C30 global and functional scales among (a) DG, (b) PPG, and (c) TG (higher scores represent better QOL). (B) Radar chart representing mean scores of the EORTC QLQ-C30 symptoms scales among (a) DG, (b) PPG, and (c) TG (lower scores represent better QOL). DG, distal gastrectomy; PPG, pylorus-preserving gastrectomy; TG, total gastrectomy; EORTC QLQ, European Organization for Research and Treatment of Cancer QOL questionnaires; QOL, quality of life.
Table 3. Comparison of mean scores on EORTC QLQ-OG25 and -STO22 among DG (n = 91), PPG (n = 56), and TG (n = 88), without chemotherapy

| Scale name               | DG vs. TG                       | PPG vs. TG                     | DG vs. PPG                      |
|--------------------------|---------------------------------|---------------------------------|---------------------------------|
|                          | Time after surgery              | Time after surgery              | Time after surgery              |
|                          | 3 Wk   | 3 Mo  | 6 Mo  | 12 Mo | 3 Wk   | 3 Mo  | 6 Mo  | 12 Mo | 3 Wk   | 3 Mo  | 6 Mo  | 12 Mo |
| **Body image**           | 76:69c*** | 74:71 | 78:69c*** | 77:67c*** | 72:69 | 73:71 | 76:69d* | 75:67 | 76:72 | 74:73 | 78:76 | 77:75 |
| **Dysphagia**            | 12:20c**  | 11:18*** | 9:17c***  | 11:15c*  | 16:20 | 10:18d*** | 9:17c***  | 9:15d*** | 12:16 | 11:10 | 9:9  | 11:9  |
| **Pain and discomfort**  | 22:25   | 19:16 | 16:14 | 16:16 | 28:25 | 18:16 | 18:14 | 17:16 | 22:28 | 19:18 | 16:18 | 16:17 |
| **Reflux**               | 12:10   | 11:10 | 9:11  | 11:12 | 17:10f* | 11:10 | 13:11 | 16:12 | 12:17 | 11:11 | 9:13 | 11:16 |
| **Eating**               | 22:31c** | 18:29c*** | 14:24c*** | 15:24d*** | 26:31 | 20:29d*** | 18:24d*** | 13:24d*** | 22:26 | 18:20 | 14:18 | 15:13 |
| **Anxiety**              | 35:38   | 36:40 | 32:37 | 33:34 | 36:38 | 35:40 | 35:37 | 33:34 | 35:36 | 36:35 | 32:35 | 33:33 |
| **Dry mouth**            | 26:25   | 16:21 | 17:21 | 22:23 | 25:25 | 13:21 | 14:21 | 17:23 | 26:25 | 16:13 | 17:14 | 22:17 |
| **Trouble with taste**   | 12:19c** | 8:16c* | 7:13c*  | 8:11  | 15:19 | 8:16d*  | 10:13  | 6:11  | 12:15 | 8:8  | 7:10 | 8:6  |
| **Hair loss**            | 4:10    | 8:7   | 14:19 | 9:14  | 5:10  | 8:7    | 18:19 | 11:14 | 4:5  | 8:8 | 14:18 | 9:11 |
| **Odynophagia**          | 16:26c** | 13:25c*** | 9:19c*** | 10:19c** | 21:26 | 16:25d*** | 12:19c*** | 8:19d*** | 16:21 | 13:16 | 9:12 | 10:8 |
| **Eating with others**   | 16:26c** | 16:28c*** | 11:23c*** | 11:21c** | 27:16c* | 13:28c*** | 12:23c*** | 9:21c*** | 16:17 | 16:13 | 11:12 | 11:9 |
| **Trouble swallowing saliva** | 1:3   | 2:5   | 1:2   | 3:2  | 1:3  | 1:5c*  | 1:2   | 1:2  | 1:1  | 2:1 | 1:1 | 3:1 |
| **Choked when swallowing** | 3:8c**   | 3:7   | 4:5   | 4:4  | 2:8d**  | 2:7c*  | 3:5   | 2:4  | 3:2  | 3:2 | 4:3 | 4:2 |
| **Trouble with coughing** | 17:17  | 12:10 | 11:12 | 11:12 | 16:17 | 10:10  | 7:12  | 6:12c* | 17:16 | 12:10 | 11:7 | 11:6c* |
| **Trouble talking**      | 2:7c**  | 5:8   | 4:3   | 3:4  | 5:7  | 2:8c*  | 2:3  | 1:4  | 2:5  | 5:2 | 4:2 | 3:1 |
| **Weight loss**          | 23:30  | 24:38c*** | 22:42c*** | 23:40c*** | 16:30c*** | 20:38d*** | 20:42d*** | 20:40d*** | 23:16 | 24:20 | 22:20 | 23:20 |

**STO22**

| Scale name               | Time after surgery              | Time after surgery              | Time after surgery              |
|--------------------------|---------------------------------|---------------------------------|---------------------------------|
|                          | 3 Wk   | 3 Mo  | 6 Mo  | 12 Mo | 3 Wk   | 3 Mo  | 6 Mo  | 12 Mo |
| **Body image**           | 76:69 | 75:70 | 78:68c* | 77:68c* | 72:69 | 73:70 | 76:68d* | 75:68 | 76:72 | 75:73 | 78:76 | 77:75 |
| **Dysphagia**            | 12:20c**  | 11:18c*** | 9:16c***  | 11:15c*  | 16:20 | 10:18d*** | 9:16c***  | 9:15d*** | 12:16 | 11:10 | 9:9  | 11:9  |
| **Pain**                 | 22:26   | 19:23 | 16:21c* | 16:20 | 26:26 | 20:23 | 19:21 | 16:20 | 22:26 | 19:20 | 16:19 | 16:16 |
| **Reflux symptoms**      | 15:12   | 13:12 | 11:11 | 12:11 | 20:12d** | 15:12 | 17:11c* | 19:11c** | 15:20c* | 13:15 | 11:17c* | 12:19c* |
| **Eating restrictions**  | 21:29c** | 17:27c*** | 14:23c*** | 15:24c** | 23:29d* | 18:27c*** | 16:23c* | 13:24c** | 21:23 | 17:18 | 14:16 | 15:13 |
| **Anxiety**              | 31:35  | 32:40c* | 29:38c* | 29:36c* | 29:35 | 30:40d** | 30:38c* | 29:36c* | 31:29 | 32:30 | 29:30 | 29:29 |
| **Dry mouth**            | 26:25   | 16:21 | 18:21 | 22:23 | 25:25 | 13:21  | 14:21 | 17:23 | 26:25 | 16:13 | 18:14 | 22:17 |
| **Taste**                | 16:22  | 13:22c* | 9:15c*  | 10:15 | 23:22 | 11:22d* | 11:15 | 8:15d* | 16:23 | 13:11 | 9:11 | 10:8 |
| **Hair loss**            | 5:9    | 9:8   | 15:19 | 11:15 | 5:9  | 8:8    | 19:15 | 10:15 | 5:5  | 9:8 | 15:19 | 11:10 |

Values are presented as mean score.
EORTC QLQ, European Organization for Research and Treatment of Cancer QOL questionnaires; DG, distal gastrectomy; PPG, pylorus-preserving gastrectomy; TG, total gastrectomy; QOL, quality of life.

aHigher scores represent better QOL; Others: lower scores represent better QOL. bNew scales in OG25 compared with STO22. cDG obtains better QOL in the comparison; dPPG obtains better QOL in the comparison. eTG obtains better QOL in the comparison.

*P < 0.05, **P < 0.01.
at postoperative 3 months when chemotherapy was started. Nonetheless, all differences disappeared at postoperative 1 year when chemotherapy was finished (Table 4). In the TG and TG + Chemo comparison, physical functioning, role functioning, nausea/vomiting, appetite loss in C30 and body image, trouble with taste, and hair loss in OG25 were observed significantly worse in the TG + Chemo at postoperative 3 months, but these differences also disappeared at the end of the follow-up (Table 4).

**DISCUSSION**

Patients who underwent gastrectomy would experience various body changes, such as change in body composition, digestive disorder, and psychological problems, especially within the first year after surgery. Objective measurements including blood test, imaging exam, and body composition analysis are widely used for assessing these changes. Although the QOL questionnaire is a subjective indicator, it has become increasingly important as a soft measurement in assessing both surgical and oncological outcomes [18]. Body weight loss is another objective indicator that varies widely among patients after surgery and is reported to have a marked impact on postoperative QOL changes [19].

Since the advanced cancer stage and poor oncologic outcome will severely affect QOL and body weight of cancer patients after surgery [20], we excluded patients who received extended radical surgery and palliative surgery in this study. Patients who suffered from tumor recurrence during follow-up were also excluded to avoid bias.

Generally, the volume of remnant stomach and the reconstruction method are 2 of the major factors for postgastrectomy weight loss. Nakamura et al. [14] reported that Billroth-I procedures resulted in significantly less weight loss than Roux-en-Y procedures, but the time point was at postoperative 3 years. In our study, gastroduodenal anastomosis patients were observed no significant advantage in terms of the change in body weight than those with gastrointestinal anastomosis (Fig. 2A). In addition, the QOL scores between DGBI and DGBII/DGRY also resulted in no difference (data not shown), which was consistent with previous reports [13,14]. Thus, we combined them as the DG group for the following analysis. As a result, patients after TG had impaired nutrition due to the loss of stomach volume, which led to significant weight loss than DG and PPG, while no difference was observed between DG and PPG. Additionally, weight loss is more serious during the first 6 months after gastrectomy (Fig. 2B). Combining with the QOL scores, we observed that symptom of appetite loss was commonly getting worse after surgery, but the speed of offset was much slower in TG than in DG/PPG (Fig. 3B). Moreover, although postoperative emotional function and symptom of anxiety usually improve because it is compared with the time of cancer diagnosis, in this study, the degree of
changelings was also different depending on the surgery group (Figs. 3A, 4B). Hence, we suggest that more serious appetite loss in patients after TG may result in more weight loss. Questionnaire items such as anxious, tensed, worried, irritable, and depressed will worsen owing to their weight loss, and finally leads to poorer QOL. As a result, supportive psychiatric care and medical intervention are needed to break this negative feedback and improve their QOL after surgery, especially within postoperative 6 months.

As a typical function-preserving gastrectomy, PPG has been demonstrated to be a feasible procedure in terms of surgical and oncologic safety [21,22]. However, whether PPG is superior to DG in the postoperative QOL still remains debated. Huang et al. [16] reported that laparoscopic-assisted (LA) PPG obtains QOL superiority to LADGBI, especially in symptom of fatigue, diarrhea, nausea/vomiting, and dry mouth at postoperative 12 months. Hosoda et al. [23] also reported that LAPPG group scored significantly better on diarrhea and dumping subscales than LADGBII group, but scored worse on the acid regurgitation subscale. While Eom et al. [24] found that patients after LAPPG might suffer from more pain and reflux symptoms compared to LADGBII. In our prospective study, we had a continuous view of QOL (preoperatively and postoperatively at 3 weeks, and 3, 6, and 12 months) in patients after gastrectomy. Results showed that the symptom of reflux in STO22 was observed worse in PPG than in DG and TG during the whole year follow-up, which was consistent with previous researches [23,24]. Although the postoperative morbidity revealed no difference between DG and PPG, more DGE was observed in PPG than in DG (Table 1). Therefore, we suggested that DGE or pyloric dysfunction might be related to more severe reflux symptoms in patients after PPG. Besides, we believed that pyloric dysfunction might also be responsible for worse symptoms of insomnia and appetite loss found in PPG group than in DG group, and these symptoms will maintain for a long period. On the other hand, PPG group showed a significantly better outcome in dyspnea and trouble with coughing at 12 months after surgery. As a result, we suggested that optimizing the surgical procedures such as retention of pyloric blood supply and manual dilatation of pylorus will be an important issue in PPG [25].

| Table 4. Comparison of mean scores on EORTC QLQ-C30 and -OG25 between chemotherapy group and chemo-free group |
|---------------------------------------------------------------|
| Scale name                        | DG (n = 91) vs. DG + Chemo (n = 15) | TG (n = 88) vs. TG + Chemo (n = 29) |
|                                 | Time after surgery | Time after surgery |
|                                 | 3 Mo                   | 6 Mo                   | 12 Mo                  | 3 Mo                   | 6 Mo                   | 12 Mo                  |
| C30 Functional scales<sup>a</sup> |                        |                        |                        |                        |                        |                        |
| Physical functioning             | 86:79<sup>i,ii</sup>  | 87:81<sup>*</sup>     | 86:83                  | 83:75<sup>iii,i,ii</sup> | 83:73<sup>iii</sup>   | 85:87                  |
| Role functioning                 | 81:86                  | 86:81                  | 87:83                  | 79:68<sup>ii</sup>     | 79:75                  | 83:79                  |
| Cognitive functioning            | 85:86                  | 83:85                  | 83:81                  | 87:83                  | 87:81                  | 86:79<sup>iii</sup>   |
| Symptom scales<sup>b</sup>       |                        |                        |                        |                        |                        |                        |
| Fatigue                         | 30:35                  | 27:33                  | 27:33                  | 34:41                  | 34:42<sup>ii</sup>    | 32:34                  |
| Nausea and vomiting             | 11:20<sup>ii</sup>    | 9:16                   | 8:10                   | 20:28<sup>ii</sup>     | 15:24<sup>ii</sup>    | 12:15                  |
| Pain                            | 14:22                  | 10:11                  | 11:10                  | 13:20                  | 11:18<sup>ii</sup>    | 11:15                  |
| Appetite loss                   | 15:43<sup>ii</sup>    | 11:33<sup>ii</sup>    | 14:26                  | 33:52<sup>ii</sup>     | 24:37<sup>ii</sup>    | 20:23                  |
| Diarrhea                        | 23:38<sup>ii</sup>    | 23:21                  | 31:40                  | 30:37                  | 29:37                  | 30:31                  |
| Financial difficulties          | 13:14                  | 14:19                  | 11:17                  | 17:23                  | 15:27<sup>ii</sup>    | 13:21                  |
| OG25 Functional scales<sup>c</sup> |                        |                        |                        |                        |                        |                        |
| Body image                      | 74:69                  | 78:76                  | 77:79                  | 71:54<sup>iii</sup>    | 69:57                  | 67:63                  |
| Symptom scales<sup>c</sup>      |                        |                        |                        |                        |                        |                        |
| Reflux                          | 11:7                   | 9:4                    | 11:2<sup>ii</sup>     | 10:17                  | 11:14                  | 12:14                  |
| Trouble with taste              | 8:24<sup>ii,iii</sup> | 7:19<sup>*</sup>     | 8:5                    | 16:35<sup>ii</sup>     | 13:33<sup>ii</sup>    | 11:15                  |
| Hair loss                       | 8:14                   | 14:21                  | 9:19                   | 7:18<sup>ii</sup>      | 19:18                  | 14:19                  |
| Odynophagia                     | 13:22<sup>ii</sup>    | 9:10                   | 10:14                  | 25:26                  | 19:27<sup>ii</sup>    | 19:19                  |
| Trouble swallowing saliva       | 2:0                    | 1:2                    | 3:0                    | 5:7                    | 2:11<sup>ii</sup>     | 2:4                    |
| Trouble talking                 | 5:7                    | 4:7                    | 3:5                    | 8:7                    | 3:9<sup>ii</sup>      | 4:3                    |

Values are presented as mean score. EORTC QLQ, European Organization for Research and Treatment of Cancer QOL questionnaires; DG, distal gastrectomy; TG, total gastrectomy; Chemo, chemotherapy; QOL, quality of life.

*Higher scores represent better QOL; 1<sup>st</sup>Lower scores represent better QOL. *DG obtains better QOL in the comparison; 1<sup>st</sup>DG + Chemo obtains better QOL in the comparison; 3<sup>rd</sup>TG obtains better QOL in the comparison. Only scales with statistical difference were showed; *P < 0.05, **P < 0.01.
preserving surgery.

Postgastrectomy syndrome is believed to be more serious after TG than DG or PPG and can result in poorer QOL [8,11]. In this study, significant differences between TG and DG/PPG in several functional and symptom scales were also observed among all the 3 questionnaires (Tables 2, 3). Although 9 of 15 scales in C30 showed worse in TG than in DG, all these differences offset at postoperative 12 months. However, in OG25 and STO22, most differences were maintained until 1 year after surgery, which indicated that patients in the TG group suffered more from postgastrectomy symptoms than in DG/PPG for a long period. The result also proved that OG25 and STO22, as complements to C30, could help measure the QOL in postgastrectomy patients more precisely.

Nowadays, adjuvant chemotherapy is widely accepted for advanced gastric cancer treatment [17]. In clinical practice, numerous patients suffer from toxicity and have negative impacts on QOL [26]. Referring to CROSS (Chemoradiotherapy for Oesophageal Cancer followed by Surgery Study) trial for esophageal or junctional cancer, although physical functioning and fatigue remain reduced after long-term follow-up, no adverse impact of neoadjuvant chemoradiotherapy plus surgery is apparent on QOL compared with surgery alone group [27]. In SCRIPT (Simply Capecitabine in Rectal Cancer after Irradiation Plus Time) trial for rectal cancer, inferior health-related QOL was reported just after completion of adjuvant chemotherapy, and all differences were resolved at 12 months after surgery [28]. While, there is still an overall lack of research on QOL in patients with adjuvant chemotherapy after gastrectomy. According to our results, we found that physical functioning, role functioning, nausea/vomiting, appetite loss in C30 and body image, trouble with taste, and hair loss in OG25 were all observed worse in the chemotherapy group, and all scales were closely related to the side effects of chemotherapy [29]. Moreover, we observed these changings after chemotherapy were more severe in the TG group than in DG, and would take more time to recover (Table 4). A similar result was also shown in the analysis of body weight loss caused by chemotherapy (Fig. 2C, D). Although worse impaired chemotherapy compliance after gastrectomy is universal, it was reported in the REGATTA (Reductive Gastrectomy for Advanced Tumor in Three Asian countries) trial that patients after TG had the worst impaired chemotherapy compliance and might result in worse overall survival than those after DG [30]. Both results suggested that the QOL after TG was worse when combined with chemotherapy than DG. Fortunately, all these changes caused by chemotherapy were reversible and were offset at postoperative 1 year, which was consistent with previous research [27]. Therefore, we suggest supportive psychiatric care to be provided once after surgery. Moreover, certain medical intervention is needed to help patients overcome side effects during their chemotherapy period. especially in patients after TG.

This study had several limitations as follows. First, it was a prospective cohort study at a single center. Patients after proximal gastrectomy were not included in this study because the number of this type of function-preserving surgery cases was not enough for further analysis during this study. And the sample size in the chemotherapy subgroups was also relatively small. Second, uneven demographic data regarding surgical approach can be a limitation (Table 1). However, in the chemofree subgroup analysis, no significant difference was found in surgical approach among patients with DG, PPG, and TG (P = 0.381). Third, the follow-up period was 12 months, and prolonging this period might be valuable to obtain a long-term QOL evaluation for patients who underwent gastrectomy in further study.

In summary, we utilized the EORTC instruments (QLQ-C30, QLQ-OG25, and QLQ-STO22) to assess the QOL among gastric cancer patients after DG, PPG, and TG. Consequently, PPG was similar to DG in terms of postoperative QOL and maintaining body weight, while TG was always inferior to both DG and PPG. Adjuvant chemotherapy can affect both body weight and QOL, especially in patients after TG, despite all changes being reversible.

SUPPLEMENTARY MATERIALS

Supplementary Tables 1, 2 and Supplementary Fig. 1 can be found via https://doi.org/10.4174/astr.2022.103.1.19.

ACKNOWLEDGEMENTS

Fund/Grant Support
This study is supported by Projects funded by the National Natural Science Foundation of China (No. 82103510).

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

ORCID iD
Chao-Jie Wang: https://orcid.org/0000-0002-7667-084X
Yun-Sukh Suh: https://orcid.org/0000-0003-3319-8482
Hyuk-Joon Lee: https://orcid.org/0000-0002-9530-647X
Ji-Hyeon Park: https://orcid.org/0000-0002-6811-8895
Shin-Hoo Park: https://orcid.org/0000-0001-9767-6100
Jong-Ho Choi: https://orcid.org/0000-0001-6963-7075
Fadhel Alzahrani: https://orcid.org/0000-0001-6034-222X
Khalid Alzahrani: https://orcid.org/0000-0002-6688-0106
Seong-Ho Kong: https://orcid.org/0000-0002-3929-796X
Do-Joong Park: https://orcid.org/0000-0001-9644-6127
REFERENCES

1. Jun JK, Choi KS, Lee HY, Suh M, Park B, Song J, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017;152:1319-28.

2. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.

3. Husson O, de Rooij BH, Kieffer J, Oerlemans S, Mols F, Aaronson NK, et al. The EORTC QLQ-C30 Summary Score as prognostic factor for survival of patients with cancer in the "real-world": results from the population-based PROFILES Registry. Oncologist 2020;25:e722-32.

4. Bae JM, Kim S, Kim YW, Ryu KW, Lee JH, Noh JH, et al. Health-related quality of life among disease-free stomach cancer survivors in Korea. Qual Life Res 2006;15:1587-96.

5. Blazebey JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004;40:2260-8.

6. Lagergren P, Fayers P, Conroy T, Stein HJ, Sezer O, Hardwick R, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the esophagus, the oesophago-gastric junction and the stomach. Eur J Cancer 2007;43:2066-73.

7. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004;13:869-8.

8. Lee JH, Lee HJ, Choi YS, Kim TH, Huh YJ, Suh YS, et al. Postoperative quality of life after total gastrectomy compared with partial gastrectomy: longitudinal evaluation by European Organization for Research and Treatment of Cancer-OG25 and STO22. J Gastric Cancer 2016;16:230-9.

9. Lee SS, Chung HY, Kwon OK, Yu W. Long-term quality of life after distal subtotal and total gastrectomy: symptom- and behavior-oriented consequences. Ann Surg 2016;263:738-44.

10. Namikawa T, Munekage E, Munekage M, Maeda H, Kitagawa H, Nagata Y, et al. Reconstruction with jejunal pouch after gastrectomy for gastric cancer. Am Surg 2016;82:510-7.

11. Takahashi M, Terashima M, Kawahira H, Nagai E, Uenosono Y, Kinami S, et al. Quality of life after total vs distal gastrectomy with Roux-en-Y reconstruction: use of the Postgastrectomy Syndrome Assessment Scale-45. World J Gastroenterol 2017;23:2068-76.

12. Inada T, Yoshida M, Ikeda M, Yumiba T, Matsumoto H, Takagane A, et al. Evaluation of QOL after proximal gastrectomy using a newly developed assessment scale (PGSAS-45). World J Surg 2014;38:3152-62.

13. Liu XF, Gao ZM, Wang RY, Wang PL, Li K, Gao S. Comparison of Billroth I, Billroth II, and Roux-en-Y reconstructions after distal gastrectomy according to functional recovery: a meta-analysis. Eur Rev Med Pharmacol Sci 2019;23:7532-42.

14. Nakamura M, Nakamori M, Ojima T, Iwahashi M, Horiiuchi T, Kobayashi Y, et al. Randomized clinical trial comparing long-term quality of life for Billroth I versus Roux-en-Y reconstruction after distal gastrectomy for gastric cancer. Br J Surg 2016;103:337-47.

15. Tomikawa M, Kusunaka D, Akahoshi T, Kohshi K, Sugimachi K, Nagao Y, et al. Quality of life after laparoscopy-assisted pylorus-preserving gastrectomy: an evaluation using a questionnaire mailed to the patients. Surg Today 2012;42:625-32.

16. Huang C, Yu F, Zhao G, Xia X. Postoperative quality of life after laparoscopy-assisted pylorus-preserving gastrectomy compared with laparoscopy-assisted distal gastrectomy for early gastric cancer. J Gastroenterol Hepatol 2020;35:1712-9.

17. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an evidence-based, multi-disciplinary approach. J Gastric Cancer 2019;19:1-48.

18. Choi JH, Han SU, Yang HK, Kim YW, Ryu KW, Park JM, et al. The pattern of postoperative quality of life following minimally invasive gastrectomy for gastric cancer: a prospective cohort from Korean multicenter robotic gastrectomy trial. Ann Surg Treat Res 2020;99:275-84.

19. Park KB, Yu B, Park JY, Kwon OK, Yu W. Impact of body mass index on quality of life after distal gastrectomy for gastric cancer. Ann Surg Treat Res 2019;96:250-8.

20. Park JH, Kim E, Seol EM, Kong SH, Park DJ, Yang HK, et al. Prediction model for screening patients at risk of malnutrition after gastric cancer surgery. Ann Surg
21. Park DJ, Kim YW, Yang HK, Ryu KW, Han SU, Kim HH, et al. Short-term outcomes of a multicentre randomized clinical trial comparing laparoscopic pylorus-preserving gastrectomy with laparoscopic distal gastrectomy for gastric cancer (the KLASS-04 trial). Br J Surg 2021;108:1043-9.

22. Suh YS, Han DS, Kong SH, Kwon S, Shin CI, Kim WH, et al. Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 2014;259:485-93.

23. Hosoda K, Yamashita K, Sakuramoto S, Katada N, Moriya H, Mieno H, et al. Postoperative quality of life after laparoscopy-assisted pylorus-preserving gastrectomy compared with laparoscopy-assisted distal gastrectomy: a cross-sectional postal questionnaire survey. Am J Surg 2017;213:763-70.

24. Eom BW, Park B, Yoon HM, Ryu KW, Kim YW. Laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer: a retrospective study of long-term functional outcomes and quality of life. World J Gastroenterol 2019;25:5494-504.

25. Zhu CC, Kim TH, Berth F, Park SH, Suh YS, Kong SH, et al. Clinical outcomes of intraoperative manual dilatation of pylorus in pylorus-preserving gastrectomy: a retrospective analysis. Gastric Cancer 2018;21:864-70.

26. Lewandowska A, Rudzki G, Lewandowski T, Próchnicki M, Rudzki S, Laskowska B, et al. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health 2020;17:6938.

27. Noordman BJ, Verdam MG, Lagarde SM, Shapiro J, Hulshof MC, van Berge Henegouwen MI, et al. Impact of neo-adjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial. Ann Oncol 2018;29:445-51.

28. van der Valk MJ, Hilling DE, Meershoeck Klein Kranenburg E, Peeters KC, Kapiteijn E, Tsonaka R, et al. Quality of life after curative resection for rectal cancer in patients treated with adjuvant chemotherapy compared with observation: results of the Randomized Phase III SCRIPT Trial. Dis Colon Rectum 2019;62:711-20.

29. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-96.

30. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17:309-18.